Creating smarter ways to fight bacteria
Leading the advancement of technologies and products
that break up biofilms and destroy bacteria.
Kane Biotech 2021 Business Update Series
Kane Biotech Inc. introduces a 5-part 2021 business update video series, meant to offer investors and other stakeholders bite-sized explainers that discuss and layout the strategies and differentiators for each of Kane’s three strategic pillars: OTC or consumer products, animal health, and wound care.
Nucleus195: Diamonds in the Rough
Interview with Kane Biotech’s Chief Scientific Officer, Gordon Guay PhD, on the compelling consumer trial results of Kane’s new DermaKB™ scalp care products.
Understanding Biofilms
The study of biofilms has increased significantly in recent years due to the growing awareness of the pervasiveness and impact of biofilms on human and animal health, as well as natural and industrial systems.
Human Health
Biofilms are estimated to be responsible for 80% of all human bacterial infections, costing billions of dollars each year.
> Learn What We’re Doing In Wound Care & Surgical
> Learn What We’re Doing In OTC Consumer Goods
Animal Health
The companion pet market in North America has grown to an estimated $62 billion in sales per year, with the oral health care segment growing rapidly at approximately 20%.
Industrial
The rapidly expanding industry for biomedical devices is estimated at $180 billion, yet it continues to suffer from microbial colonization. Microbial infections can develop on all medical devices and hard surfaces.
R+D
For over 10 years Kane Biotech’s R+D division has been developing new technologies and innovations leading to 52 patents and patents pending in biotechnology focusing primarily on biofilm.
Patents and Patents Pending